Guia prático da Associação Brasileira de Alergia e Imunologia para o diagnóstico e tratamento das urticárias baseado em diretrizes internacionais
A practical guide of the Brazilian Association of Allergy and Immunology to the diagnosis and treatment of urticaria based on international guidelines
Luis Felipe Ensina; Solange Oliveira Rodrigues Valle; Régis Albuquerque Campos; Rosana Agondi; Paulo Criado; Roberta Buense Bedrikow; Joachim W. Fluhr; Dirceu Solé; Torsten Zuberbier
Resumo
A urticária crônica espontânea afeta mais de um milhão de brasileiros e impacta significativamente em sua qualidade de vida. Para atualizar as recomendações quanto ao seu diagnóstico e tratamento, especialistas de todo o mundo reúnem-se a cada quatro anos em Berlim e revisam todas as novas evidências que justifiquem modificações na diretriz internacional. Este artigo discute as principais recomendações propostas na versão atual da diretriz.
Palavras-chave
Abstract
Chronic spontaneous urticaria affects more than one million Brazilians and significantly impacts their quality of life. In order to update the recommendations on diagnosis and treatment, experts from all over the world meet every 4 years in Berlin to review all the new evidence that can support modifications to the international guidelines. This paper discusses the main recommendations proposed in the current version of the guidelines.
Keywords
Referências
1. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73:1393‑414.
2. Davis MDP, van der Hilst JCH. Mimickers of Urticaria: Urticarial Vasculitis and Autoinflammatory Diseases. J Allergy Clin Immunol Pract. 2018;6:1162‑70.
3. Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy. 2014;69:602‑16.
4. Simons FER, Ardusso LR, Bilò MB, Cardona V, Ebisawa M, ElGamal YM, et al. International consensus on (ICON) anaphylaxis. World Allergy Organ J. 2014;7:9.
5. Sabroe RA. Acute urticaria. Immunol Allergy Clin N Am. 2014;34:11‑21.
6. Sole D, Ivancevich JC, Borges MS, Coelho MA, Rosario NA, Ardusso LRF, et al. Anaphylaxis in Latin America: a report of the online Latin American survey on anaphylaxis (OLASA). Clinics. 2011;66:943‑7.
7. Jares EJ, Sanchez-Borges M, Cardona-Villa R, Ensina LF, Arias-Cruz A, Gómez M, et al. Multinational experience with hypersensitivity drug reactions in Latin America. Ann Allergy Asthma Immunol. 2014;113:282‑9.
8. Modena B, White AA, Woessner KM. Aspirin and Nonsteroidal Antiinflammatory Drugs Hypersensitivity and Management. Immunol Allergy Clin North Am. 2017;37:727-49.
9. Rutnin NO, Kulthanan K, Tuchinda P, Jongjarearnprasert K. Druginduced urticaria: causes and clinical courses. J Drugs Dermatol. 2011;10:1019‑24.
10. Tarbox JA, Gutta RC, Radojicic C, Lang DM. Utility of routine laboratory testing in management of chronic urticaria/angioedema. Ann Allergy Asthma Immunol. 2011;107:239‑43.
11. Kolkhir P, André F, Church MK, Maurer M, Metz M. Potential blood biomarkers in chronic spontaneous urticaria. Clin Exp Allergy. 2017;47:19‑36.
12. Hide M, Hiragun M, Hiragun T. Diagnostic tests for urticaria. Immunol Allergy Clin N Am. 2014;34:53-72.
13. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2017;139:1772‑81.
14. Konstantinou GN, Asero R, Ferrer M, Knol EF, Maurer M, Raap U, et al. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy. 2013;68:27‑36.
15. Moestrup K, Ghazanfar MN, Thomsen SF. Patient-reported outcomes (PROs) in chronic urticaria. Int J Dermatol. 2017;56:1342-48.
16. Valle SOR, Dortas-Junior SD, Dias GAC, Motta AA, Falcao-doAmaral CS, Martins EAPR, et al. Ferramentas para avaliação e acompanhamento da urticária crônica. Arq Asma Alerg Imunol. 2018;2:209-24.
17. Baiardini I, Braido F, Bindslev-Jensen C, Bousquet PJ, Brzoza Z, Canonica GW, et al. Recommendations for assessing patientreported outcomes and health-related quality of life in patients with urticaria: a GA(2)LEN taskforce position paper. Allergy. 2011;66:840-4.
18. Weller K, Zuberbier T, Maurer M. Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. J Eur Acad Dermatol Venereol. 2015;29 suppl 3:38-44.
19. Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073‑8.
20. Dias GA, Pires GV, Valle SO, França AT, Papi JA, Dortas SD Jr, et al. Cross-cultural adaptation of the Brazilian-Portuguese version of the chronic urticaria quality-of-life questionnaire - CU-Q2oL. Allergy. 2011;66:1487-93.
21. De-Aquino BM, Lacerda AE, Marcelino FC, da-Silva BG, CameloNunes IC, Sole D, et al. Tradução e adaptação transcultural para o idioma português (Brasil) do instrumento “Angioedema Activity Score”. Arq Asma Alerg Imunol. 2018;2:351-6.
22. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CEH, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA 2LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71:780‑802.
23. Jáuregui I, Ferrer M, Montoro J, Dávila I, Bartra J, del Cuvillo A, et al. Antihistamines in the treatment of chronic urticaria. J Investig Allergol Clin Immunol. 2007;17:41-52.
24. Zuberbier T. Pharmacological rationale for the treatment of chronic urticaria with second-generation non-sedating antihistamines at higher-than-standard doses. J Eur Acad Dermatol Venereol. 2011;26:9‑18.
25. Kaplan AP. Chronic Spontaneous Urticaria: Pathogenesis and Treatment Considerations. Allergy Asthma Immunol Res. 2017;9:477‑6.
26. Schulz S, Metz M, Siepmann D, Luger TA, Maurer M, Ständer S. [Antipruritic efficacy of a high-dosage antihistamine therapy. Results of a retrospectively analysed case series]. Hautarzt. 2009;60:564‑8.
27. Casale TB, Win PH, Bernstein JA, Rosén K, Holden M, Iqbal A, et al. Omalizumab response in patients with chronic idiopathic urticaria: Insights from the XTEND-CIU study. J Am Acad Dermatol. 2018;78:793‑5.
28. Wang L, Ke X, Kavati A, Wertz D, Huang Q, Willey VJ, et al. Real-world treatment patterns and outcomes of omalizumab use in patients with chronic idiopathic urticaria. Curr Med Res Opin. 2018;34:35‑9.
29. Ensina LF, Valle SOR, Juliani AP, Galeane M, Vieira dos Santos R, Arruda LK, et al. Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience. Int Arch Allergy Immunol. 2016;169:121‑4.
30. Saini SS, Bindslev-Jensen C, Maurer M, Grob J-J, Bülbül Baskan E, Bradley MS, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67‑75.
31. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141:638‑49.
32. Kaplan AP, Giménez-Arnau AM, Saini SS. Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria. Allergy. 2017;72:519‑33.
33. Gericke J, Metz M, Ohanyan T, Weller K, Altrichter S, Skov PS, et al. Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. J Allergy Clin Immunol. 2017;139:1059‑61.
34. Türk M, Carneiro-Leão L, Kolkhir P, Bonnekoh H, Buttgereit T, Maurer M. How to Treat Patients with Chronic Spontaneous Urticaria with Omalizumab: Questions and Answers. J Allergy Clin Immunol Pract. 2019. Epub ahead of print.
35. Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy Clin Immunol Pract. 2013;1:433‑40.
36. Savic S, Marsland A, McKay D, Ardern-Jones MR, Leslie T, Somenzi O, et al. Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care. Allergy Asthma Clin Immunol. 2015;11:21.
37. Vena GA, Maurer M, Cassano N, Zuberbier T. Alternative treatments for chronic spontaneous urticaria beyond the guideline algorithm. Curr Opin Allergy Clin Immunol. 2017;17:278‑85.
38. Maurer M, Rosén K, Hsieh H-J, Saini S, Grattan C, Gimenéz-Arnau A, et al. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria. N Engl J Med. 2013;368:924‑35.
39. Zuberbier T, Bernstein JA. A Comparison of the United States and International Perspective on Chronic Urticaria Guidelines. J Allergy Clin Immunol Pract. 2018;6:1144‑51.
40. Sarkar TK, Sil A, Pal S, Ghosh C, Das NK. Effectiveness and safety of levocetirizine 10 mg versus a combination of levocetirizine 5 mg and montelukast 10 mg in chronic urticaria resistant to levocetirizine 5 mg: A double-blind, randomized, controlled trial. Indian J Dermatol Venereol Leprol. 2017;83:561‑8.
41. Akenroye AT, McEwan C, Saini SS. Montelukast reduces symptom severity and frequency in patients with angioedema-predominant chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2018;6:1403‑5.
Submetido em:
02/12/2019
Aceito em:
16/12/2019
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email